The overexpression of NRF2 could also increase the risk of cytarabine resistance in a ROS-independent manner by inhibiting MutS Homolog 2 (MSH2) expression in acute myeloid leukemia (AML) [72]. The gene discussed is MSH2; the disease is acute myeloid leukemia.